ASCO 2026: Monjuvi to rival Polivy in 1L DLBCL after strong Phase III results

Incyte’s mAb Monjuvi with chemotherapy beat chemotherapy alone in treating first-line diffuse large B-cell lymphoma. Incyte’s mAb Monjuvi with chemotherapy beat chemotherapy alone in treating first-line diffuse large B-cell lymphoma. Few agents define SoC for first-line DLBCL, with 40% of patients going on to develop R/R disease. Credit LindseyRN/Shutterstock.com Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has seen major advances in recent years, with the arrival of next-generation chimeric antigen receptor T-cell (CAR-T) therapies, bispecific T-cell engagers, and antibody-drug conjugates. This contrasts with the first-line setting, where Roche/Biogen’s Rituxan (rituximab) plus chemotherapy (cyclophosphamide, doxorubicin, vincristine, and…

Source: Clinical Trials Arena